The Oncology Market in 2026

The US oncology market was valued at roughly $81.34 billion in 2025 and is forecast to reach about $211.78 billion by 2034, a compound annual growth rate near 11.75% (Precedence Research, 2025). That growth is demand-led: an ageing population, earlier detection, and a wave of targeted and immunotherapy drugs that turn what used to be a few standard regimens into dozens of biomarker-specific protocols.

Where that money sits matters for your plan. Hospitals and dedicated cancer specialty centers captured about 48% of revenue share in 2024 (Precedence Research, 2025), and the independent, physician-owned side of the market has been shrinking under acquisition pressure. The Community Oncology Alliance counted 1,249 community oncology practices and clinics acquired, merged, or closed over a roughly ten-year window (Community Oncology Alliance, Practice Impact Report). A business plan that ignores that consolidation pressure reads as naive to any lender who knows the sector.

Who your patients are, and who refers them

An oncology practice rarely wins patients through advertising. Volume comes from referral relationships: primary-care physicians, surgeons, radiologists, and screening programs that flag a suspicious result and need somewhere to send it. Your business plan should name the referral sources in your catchment, estimate the number of new cancer cases in that population each year, and explain how you will earn a share of those referrals away from the incumbent hospital system. A plan that treats patients as a generic "target market" rather than a referral-driven pipeline will not convince anyone who has run a practice.

Three buyer-side realities shape the model. First, the payer, not the patient, sets most of your revenue through negotiated reimbursement rates. Second, a meaningful share of patients are on Medicare, which fixes drug-administration economics tightly. Third, geography matters more than in almost any other clinical specialty because patients on a weekly infusion schedule will not drive ninety minutes each way; catchment density is a hard constraint on volume.

The consolidation backdrop also creates an opening that a sharp plan can exploit. As hospital systems and large platforms have absorbed independent practices, many communities have ended up with a single dominant cancer-care provider and longer waits. A new independent practice that can credibly promise shorter time-to-treatment, evening or weekend infusion slots, and continuity with a named oncologist has a real differentiator, and that differentiator belongs in the market section of the plan, backed by local wait-time and travel-distance evidence rather than asserted in the abstract.

Reading the demand signals in your catchment

Strong oncology plans quantify demand from the bottom up rather than top down. Start with the population of the catchment, apply the local cancer-incidence rate, and estimate how many new diagnoses occur each year that would plausibly need outpatient infusion or hematology care. Then subtract the share already captured by the dominant hospital system, and what remains is your realistic addressable referral volume. A plan that says "the US oncology market is $81 billion" without translating that to "roughly N new cases a year in our forty-minute drive-time radius" is not a plan a lender can act on. The national figure sets context; the catchment figure sets the forecast.

SBA Funding for a Cancer-Care Practice

Most independent oncology practices in the US are financed with a blend of an SBA 7(a) loan, equipment financing for the infusion and imaging hardware, and partner capital from the founding physicians. The SBA 7(a) program lends up to $5 million, and medical practices are a familiar, lender-friendly category because the underlying cash flow is recurring and insurance-backed.

What makes oncology different from a dentist or a physical-therapy clinic is the drug pass-through. A 7(a) lender looking at a practice doing, say, $9M in revenue will discount most of that top line because it is chemotherapy cost flowing straight back out to the drug wholesaler. Underwriters want to see the margin line, not the revenue line. The practices that get funded present a drug-margin sensitivity table and a break-even tied to infusion-chair utilisation rather than a single hockey-stick revenue chart.

• Typical 7(a) ask for a 6–10 chair startup practice: $750K–$2M, often paired with a separate equipment lease so the loan is not carrying depreciating hardware.
• Collateral and injection: lenders generally expect a 10% equity injection and may take a lien on receivables; physician personal guarantees are standard.
• Documentation that moves the file: signed payer-contract letters of intent, a credentialing timeline, and a realistic ramp showing chairs filling over 12–18 months rather than from day one.
• Working capital buffer: drug purchasing is cash-intensive and reimbursement lags 30–90 days, so the plan must fund a drug-inventory float, not just buildout.

In the UK, the equivalent early-stage route is the government-backed Start Up Loan (up to £25,000 per founder at a 6% fixed rate), though for a CQC-registered cancer clinic that figure is a fraction of what is needed; most UK private oncology ventures are funded through commercial healthcare lenders, asset finance, and equity. Either way, the financial model in your plan does the heavy lifting.

Investors, as opposed to lenders, look at the same practice through a different lens. A bank wants to know it will be repaid and tests downside; an equity investor wants to know the practice can scale into a multi-site group or become an attractive acquisition for one of the consolidating platforms. If you are raising equity rather than debt, the plan should sketch the growth path beyond the first clinic: a second location, a service-line addition such as radiation oncology, or a roll-up thesis. Given that platforms have spent billions acquiring community practices, including a major nine-figure transaction for a controlling stake in the largest US independent practice, a credible exit narrative is not fantasy; it is the lived pattern of the sector. The plan should name that pattern and position the practice within it.

What It Costs to Open the Doors

A community oncology practice with its own infusion suite typically needs $250K to $1.2M (about £200K to £950K) before the first patient is treated. The range is wide because it depends on whether you build a pharmacy clean room on site, how many infusion chairs you start with, and whether diagnostic imaging is in-house or referred out.

Cost breakdown line by line

• Oncology-specialty EHR: a general EHR runs $300–$700 per provider monthly, but oncology modules for chemotherapy order management, regimen libraries and infusion scheduling push that to $600–$1,300 per provider monthly, with $30K–$150K in setup for a small practice (TactionSoft, 2026). Oncology-specific add-on modules alone can add $10K–$50K each.
• Infusion suite and pharmacy: chairs, pumps, refrigeration, biosafety cabinets and a USP-compliant clean room for compounding are the single biggest physical investment.
• Professional liability / indemnity: $14K–$65K a year. Oncology carries a high malpractice exposure, so this is recurring six figures over a few years, not a one-off.
• Licensing, DEA & certification: $5K–$25K to cover state medical licensing, DEA registration for controlled and chemotherapeutic agents, and board-certification maintenance.
• Drug-inventory working capital: because you buy chemotherapy before you are reimbursed, budget a six-figure float that a buildout-only plan will miss.

The funding routes that fit this profile are an SBA 7(a) loan for the buildout, equipment financing or leasing for chairs and imaging, a working-capital line for drug inventory, and physician partner equity. Grants are rare for a for-profit clinic, though research-active practices sometimes access trial-sponsor funding that offsets specific costs.

One decision quietly drives a large share of the range above: build versus refer for imaging and lab. A practice that puts a point-of-care lab and basic imaging on site captures ancillary revenue and shortens the patient journey, but it also adds CLIA obligations, equipment cost, and staffing. A practice that refers those out launches leaner and faster but hands margin to a partner. Neither is wrong; what matters is that the plan states the choice and shows the cost and revenue consequences rather than leaving it implicit. Lenders read an explicit build-versus-refer rationale as a sign the founders have actually thought through their operating model.

Phasing also reduces the capital ask. Many successful independent practices open with a smaller chair count and a referred-imaging model, prove utilisation over the first year, then add chairs, in-house imaging, or a second location once the referral pipeline is established. Presenting the launch as a phased build, with the larger spend gated behind milestones the lender can see, is far more financeable than asking for the full $1.2M on day one against unproven volume.

Equipment & Infusion-Suite Checklist

Capacity in an oncology practice is measured in infusion chairs, and chair utilisation is the metric your whole financial model hinges on. The equipment list below is what a community medical-oncology practice with an on-site infusion suite typically budgets for; radiation oncology adds linear accelerators and shielding that move the figures into a different order of magnitude.

Named oncology EHR platforms worth pricing against each other include Varian and Flatiron Health at the sophisticated end (well above $1,300 per provider monthly) and CureMD and similar mid-market systems at lower price points (CureMD oncology EHR pricing analysis). The trap is buying a general primary-care EHR and discovering it cannot handle multi-day chemotherapy regimens, dose rounding, or infusion scheduling; the retrofit costs more than choosing correctly at the start.

When you size the suite, work backward from the volume forecast rather than guessing a chair count. If the catchment analysis points to roughly 9,000 infusion visits a year and a chair safely turns over a set number of patients per day, the arithmetic tells you how many chairs you need at target utilisation, plus a small buffer for no-shows and reaction-management overruns. Buying too few chairs caps revenue; buying too many strands capital in idle furniture and floor space. The equipment list, in other words, is downstream of the demand model, and a plan that derives one from the other reads as far more rigorous than a round-number wish list.

Leasing versus buying is the other equipment decision worth spelling out. Chairs, pumps and imaging hardware depreciate, and an SBA lender often prefers the loan to fund leasehold improvements and working capital while a separate equipment lease carries the depreciating assets. Stating that split in the plan keeps the loan request clean and signals that the founders understand how lenders like to see risk allocated.

How the Money Is Actually Made

This is where most oncology business plans go wrong, so it is worth being blunt. The revenue figure on the top line is large and mostly illusory as profit, because a significant share of it is high-value chemotherapy and supportive-care drugs passing straight through the practice (VMG Health). Four revenue streams sit underneath it:

• Buy-and-bill drug margin: the spread between the practice's acquisition cost for a drug and the reimbursement it collects. This is the single largest contributor and the most exposed to policy change.
• Drug-administration and infusion fees: billed per administration; tied directly to chair throughput.
• Evaluation-and-management (E/M) visits: consultations, follow-ups and care planning.
• Ancillary services: in-house lab, imaging, pharmacy and, where applicable, clinical-trial sponsor payments.

The reason the drug margin dominates and also terrifies underwriters is that it is set by forces entirely outside the practice's control. Average sales price reimbursement formulas, biosimilar substitution, payer formularies, and periodic policy reform can all move the spread without warning. A practice that earns its operating profit almost entirely from drug margin is, in effect, running a thin-margin distribution business with a clinical front end. The strategic answer in a good plan is diversification: grow E/M and ancillary revenue so the practice is not solvent only when the drug spread cooperates. Underwriters reward a plan that shows the non-drug revenue lines carrying a meaningful and growing share of contribution over the forecast period.

It is also worth being precise about what "profit" means here. Reported industry net margins span a wide 5% to 31% range, but the high end usually reflects practices with favourable payer mix, mature ancillary lines, or scale that a startup will not have on day one (CancerNetwork). For a new independent practice, modelling toward the 12% to 18% band in the first three years is honest; promising 30% from launch is the kind of claim that makes a lender close the file.

The 340B program is the elephant in the room. An independent practice and a 340B hospital are reimbursed the same amount for the same drug, but the hospital buys it far cheaper. In one widely cited comparison, an independent practice purchasing Herceptin for a Medicare breast-cancer patient at $66,107 collected a $3,966 spread, while a 340B hospital bought the same drug at $43,168 and kept a $26,905 spread — roughly 6.8 times the margin on an identical patient (Pharmacy Times). Because 340B is not available to non-hospital independent practices, your plan must model revenue without it and explain how the practice stays solvent on commercial-payer drug margin and administration fees.

Licensing Across the US, UK & Australia

Cancer care is among the most heavily regulated outpatient activities there is, and the licensing layer is jurisdiction-specific. A credible plan names the actual bodies and timelines rather than waving at "compliance". The pattern repeats across every country: a clinician credential proving the doctor is qualified, a facility license proving the premises are safe to deliver treatment, and a payer or reimbursement registration that lets the practice actually collect for the care it gives. Miss any one of the three and the practice cannot legally treat and bill, so each belongs in the launch timeline with a realistic date attached.

United States

• State medical license + DEA registration: each treating physician needs an active state license and DEA registration to handle controlled and chemotherapeutic agents (DEA registration is roughly $888 for three years). Budget 60–120 days.
• Board certification: payers expect treating physicians to hold ABIM medical-oncology or hematology certification (Oncology Practice Management).
• Commission on Cancer accreditation: optional but payer-preferred; the American College of Surgeons accredits over 1,500 cancer programs nationally.
• HIPAA and, if you run a lab, CLIA certification: patient-privacy and lab-quality obligations are continuous, not one-time.

United Kingdom

• CQC registration: a private oncology clinic must register with the Care Quality Commission as a provider of regulated activities before treating patients; expect roughly 10–12 weeks and an annual fee scaled to the size of the service.
• GMC registration + Specialist Register: consultants need full General Medical Council registration with a licence to practise and entry on the Specialist Register for clinical or medical oncology; international medical graduates may go through the Portfolio Pathway (formerly CESR), which can take months (GMC).
• Controlled-drug and radiation governance: handling cytotoxics and any radiotherapy brings additional Home Office controlled-drug licensing and ionising-radiation regulations.

Australia (third jurisdiction)

In Australia, treating physicians register with AHPRA and hold fellowship of the Royal Australasian College of Physicians (medical oncology) or RANZCR (radiation oncology). A private day-hospital or oncology facility is licensed at state or territory level, and a Medicare provider number is needed for patients to claim rebates. The pattern is the same everywhere: a clinician credential plus a facility license plus a payer/reimbursement registration.

Five Mistakes That Sink Oncology Plans

• Modelling top-line revenue as if it were margin. Most of it is drug pass-through. Lenders know this; a plan that does not separate the two looks amateur.
• Assuming 340B pricing. It is not available to non-hospital independent practices. Building a model on hospital-level drug margin is a fatal error.
• Underbudgeting the EHR. A primary-care system cannot run chemotherapy regimens; the oncology module is a $10K–$50K line item, not an afterthought.
• Ignoring chair utilisation. Infusion chairs are your capacity ceiling. A plan with no utilisation assumption has no real revenue forecast.
• Treating indemnity insurance as a minor cost. At $14K–$65K a year, professional liability is a recurring six-figure exposure across a startup's early years.

Avvale's bespoke plans model each of these explicitly, which is usually the difference between a plan a lender takes seriously and one that gets a polite decline.

Operations, Staffing & Payer Mix

The operations plan is where an oncology business plan proves it was written by someone who understands the clinic, not just the spreadsheet. Three operational levers decide whether the financial model holds: staffing ratios, the payer mix, and the drug supply chain.

Staffing the practice

An infusion-equipped practice runs on more than its oncologists. A typical eight-to-twelve chair clinic needs medical oncologists or hematologists as the clinical core, advanced-practice providers (nurse practitioners or physician assistants) to extend physician capacity, oncology-certified infusion nurses at a ratio that keeps chairs safely supervised, a pharmacist or pharmacy technician for compounding, and a disproportionately large billing and prior-authorisation team. That last group surprises first-time founders: payers impose heavy administrative demands, and the cost of the staff needed to satisfy them is one of the fastest-rising overheads in the specialty (VMG Health). Your staffing plan should tie headcount to chair count and visit volume rather than picking round numbers.

Payer mix is destiny

Two practices with identical chairs and identical patient counts can have very different margins purely because of payer mix. Medicare fixes drug-administration economics tightly and reimburses the drug itself on a formula basis, while commercial payers negotiate rates that often carry a healthier spread. A practice weighted heavily toward Medicare and Medicaid will see thinner drug margin than one with a strong commercial book, and the financial model must show the assumed mix explicitly. Underwriters will stress this: a forecast that quietly assumes a rich commercial mix without local evidence is the kind of optimism that gets a plan declined.

The drug supply chain

Because the buy-and-bill model means you purchase expensive drugs before reimbursement arrives, your relationship with a group purchasing organisation or specialty distributor is a genuine operational asset (CancerNetwork). The plan should describe purchasing arrangements, inventory controls to avoid waste on short-dated high-value drugs, and the working-capital float that bridges the gap between paying the wholesaler and collecting from the payer. Drug waste and inventory mismanagement quietly erode margin in practices that treat pharmacy as an afterthought.

Prior authorisation and the revenue-cycle bottleneck

One operational reality deserves its own line in the plan because it surprises nearly every first-time founder: the time and labour consumed by prior authorisation. Before many regimens can be administered, the payer must approve them, and that approval can take days and several rounds of clinical documentation. A delayed authorisation does not just frustrate patients; it stalls the revenue cycle, because a chair sits empty and a drug sits unbilled. Practices that run lean on authorisation staff end up with utilisation gaps that no amount of marketing fixes. The operations section should size this team realistically and, ideally, describe the workflow or software that keeps authorisations moving so chairs stay full.

Tie all of this back to a single operating metric and the plan becomes legible to a lender: contribution per filled chair-hour. Every operational lever, staffing ratios, payer mix, drug purchasing, and authorisation throughput, ultimately shows up as either more filled chair-hours or more contribution per hour. A founder who can articulate the business in those terms demonstrates exactly the command of unit economics that turns a polite-decline plan into a funded one.

Oncology Plan Glossary for Founders and Lenders

A few terms recur throughout an oncology business plan, and using them precisely signals competence to anyone reviewing the document.

• Buy-and-bill: the model where the practice purchases a drug, administers it, and then bills the payer, earning the spread between acquisition cost and reimbursement. It is the core of independent-practice economics.
• 340B: a federal drug-pricing program offering deep discounts to eligible hospitals; not available to non-hospital independent practices, which is why it skews the competitive field toward hospital systems.
• Average sales price (ASP): the benchmark on which Medicare bases drug reimbursement, typically ASP plus a small percentage; changes here move practice margin directly.
• Infusion chair utilisation: the share of available chair-hours actually filled with treating patients; the single most important capacity and revenue driver in the model.
• Prior authorisation: the payer approval required before many regimens can be administered and billed; a major source of both administrative cost and revenue-cycle delay.
• Payer mix: the proportion of patients covered by Medicare, Medicaid and commercial insurers, which largely determines blended drug margin.
• Biosimilar: a lower-cost near-copy of a biologic drug; substitution can compress the margin on what were once high-spread products.

Sample Plan Preview

The full template gives you this structure to fill in with your own catchment, payer mix and chair count. The sample above shows the tone lenders respond to: specific about geography, specific about the funding ask, and candid about the one risk every oncology underwriter probes, which is drug-margin sensitivity. Notice what it does not do. It does not lead with the size of the national cancer market, it does not promise immediate full chair utilisation, and it does not bury the pass-through nature of drug revenue. Those three habits separate a fundable oncology plan from a hopeful one.

What's Inside the Template

The oncology practice business plan template is an editable Word document structured for lenders, the SBA, and private investors who understand cancer-care economics.

• Executive summary framework with a funding-ask block
• Market and referral-pipeline analysis section with prompts for catchment incidence data
• Service-line definition (medical oncology, hematology, infusion, ancillary)
• Operations plan covering infusion-chair capacity and pharmacy compounding
• Staffing plan: oncologists, advanced-practice providers, infusion nurses, pharmacy, billing
• Regulatory and licensing checklist for your jurisdiction
• Five-year financial projections with a drug-margin sensitivity model
• Break-even analysis tied to infusion-chair utilisation
• Risk register covering reimbursement, payer concentration and clinical liability

Prefer not to write it yourself? See our market research and content service or a fully bespoke business plan. You can also browse all our free business plan templates or read related guides such as our medical clinic business plan template.

Frequently Asked Questions